Natural cytotoxicity receptor ligands (NCR ligands)

Natural cytotoxicity receptor (NCR) ligands, specifically those for NKp30 (NCR3) and NKp44 (NCR2), are a diverse group of molecules expressed on the surface of tumor cells or secreted into the microenvironment that serve as critical triggers for Natural Killer (NK) cell activation (Pazina et al., 2017, Frontiers in Immunology). The most prominent ligand for NKp30 is B7-H6 (NCR3LG1), a member of the B7 family that is highly expressed in various cancers—including melanoma, lymphoma, and breast cancer—but is largely absent from healthy tissues, making it a highly specific therapeutic target (Brandt et al., 2009, Journal of Experimental Medicine). Other ligands include BAG6 (BAT3) for NKp30, and PDGF-DD or a specific isoform of MLL5 for NKp44 (Barrow et al., 2018, Cell; Baychelier et al., 2013, Blood). These ligands interact with NCRs on NK cells to initiate signaling cascades that lead to the release of cytotoxic granules (perforin and granzymes) and pro-inflammatory cytokines like IFN-gamma. In the context of cancer, tumors often downregulate these ligands or shed them as soluble forms (e.g., soluble B7-H6) to evade immune detection and induce NK cell exhaustion (Kruse et al., 2014, OncoImmunology). Therapeutic strategies currently under development include bispecific antibodies (NK-cell engagers) and CAR-NK cells designed to recognize these ligands and restore potent anti-tumor immunity.

Other names

B7-H6NCR3LG1BAG6BAT3PDGF-DDMLL5NKp30 ligandsNKp44 ligandsNCR3 ligandsNCR2 ligands

Activation of NK cell-mediated cytotoxicity through binding to NKp30 (NCR3) or NKp44 (NCR2) receptors on NK cells.